πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

1,265 results for β€œGan” Clear

  1. Digoxin

    The First People's Hospital of Lianyungang

    Healthy

    phase 1 small molecule completed

    1 trial

  2. Eprolidone

    The First People's Hospital of Lianyungang

    Chronic Heart Failure Patients

    phase 1 small molecule active

    1 trial

  3. Esketamine injection group (0.25 mg/kg)

    The First People's Hospital of Lianyungang

    Esketamine

    phase 1 small molecule active

    1 trial

  4. Exenatide Circular RNA-Lipid Nanoparticle Injection（ CR059οΌ‰οΌ‰

    The First People's Hospital of Lianyungang

    T2DM

    phase 1 small molecule active

    1 trial

  5. FT-003

    The First People's Hospital of Lianyungang

    Diabetic Macular Edema

    phase 1 gene therapy active

    1 trial

  6. FT-003

    The First People's Hospital of Lianyungang

    Neovascular Age-related Macular Degeneration

    phase 1 gene therapy active

    1 trial

  7. Ferric Carboxymaltose Injection

    The First People's Hospital of Lianyungang

    Healthy Adult

    phase 1 small molecule completed

    1 trial

  8. GK01 Injection

    The First People's Hospital of Lianyungang

    Advanced Solid Tumors

    phase 1 small molecule active

    1 trial

  9. GMCN-508B (LentiRed)

    The First People's Hospital of Lianyungang

    Transfusion Dependent Beta-Thalassemia

    phase 1 gene therapy active

    1 trial

  10. GPC3 and/or TGFΞ² targeting CAR-T cells

    The First People's Hospital of Lianyungang

    Hepatocellular Carcinoma

    phase 1 mab active

    1 trial

  11. GPRC5D CAR-T cell intravenous infusion

    The First People's Hospital of Lianyungang

    Plasma Cell Dyscrasias

    phase 1 mab active

    1 trial

  12. GST-HG121 tablets

    The First People's Hospital of Lianyungang

    Pharmacokinetics

    phase 1 small molecule active

    1 trial

  13. Gallium-68 NODAGA-JR11

    The First People's Hospital of Lianyungang

    Neuroendocrine Tumors

    phase 1 small molecule active

    1 trial

  14. HER2 Tumor Vaccine

    The First People's Hospital of Lianyungang

    Adenocarcinoma - GEJ

    phase 1 mab active

    1 trial

  15. HSK3486

    The First People's Hospital of Lianyungang

    Chronic Renal Impairment

    phase 1 small molecule completed

    1 trial

  16. HSK3486

    The First People's Hospital of Lianyungang

    Healthy Elderly Subjects

    phase 1 small molecule completed

    1 trial

  17. HY-2003 (10 mg/ml), BELKYRA and placebo

    The First People's Hospital of Lianyungang

    Moderate or Severe Submental Fullness

    phase 1 small molecule active

    1 trial

  18. Hema-NeoTIL01

    The First People's Hospital of Lianyungang

    Leukemia, Myeloid, Acute

    phase 1 mab active

    1 trial

  19. Human BCMA targeted T Cells Injection

    The First People's Hospital of Lianyungang

    Multiple Myeloma

    phase 1 small molecule active

    1 trial

  20. Human Umbilical Mesenchymal Stem Cells

    The First People's Hospital of Lianyungang

    Osteoarthritis, Knee

    phase 1 mab active

    1 trial

  21. Human amniotic-derived mesenchymal stem cells

    The First People's Hospital of Lianyungang

    Chronic Kidney Diseases

    phase 1 mab active

    1 trial

  22. Hydronidone capsules

    The First People's Hospital of Lianyungang

    Liver Fibrosis

    phase 1 small molecule active

    1 trial

  23. IBR733 Cell Injection

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 1 mab active

    1 trial

  24. ICI201

    The First People's Hospital of Lianyungang

    Relapsed/Refractory Multiple Myeloma

    phase 1 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources